Scarica l'app Stockscreener
25.88
0.73%
-0.19
Dopo l'orario di chiusura:
25.88
Precedente Chiudi:
$26.07
Aprire:
$26.03
Volume 24 ore:
504.42K
Relative Volume:
0.72
Capitalizzazione di mercato:
$1.11B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
17.85
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
-0.54%
1M Prestazione:
+9.80%
6M Prestazione:
+8.28%
1 anno Prestazione:
+37.37%
Intervallo 1D:
$25.84
$26.36
Intervallo di 1 settimana:
$25.84
$26.70
Portata 52W:
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.88 | 1.12B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Big and small, Bay Area companies catch eye of activist shareholders at year's end - The Business Journals
Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale - marketscreener.com
DOMA to nominate three directors to Pacira board, urges company sale By Investing.com - Investing.com Nigeria
DOMA Perpetual Pushes for Strategic Changes at Pacira BioSciences (PCRX) - GuruFocus
Pacira (PCRX) Faces Push for Leadership Change and Strategic Rev - GuruFocus
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - Seeking Alpha
Doma Perpetual Capital Management asserts Pacira BioSciences's board to pursue sale of company - marketscreener.com
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. - PR Newswire
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc. - MarketBeat
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC - MarketBeat
Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Neelam Linens and Garments (India) Limited Benefit From Sector TailwindsConsumer Goods Stocks & Free Stock Index Interpretations - bollywoodhelpline.com
OA Gets a Data-Driven PROBE Makeover - Orthopedics This Week
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Investors May Respond To Pacira BioSciences (PCRX) Joining AI-Driven PROBE Osteoarthritis Consortium - Sahm
Pacira BioSciences (PCRX) price target decreased by 18.47% to 30.77 - MSN
Price-Driven Insight from (PCRX) for Rule-Based Strategy - news.stocktradersdaily.com
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock maintain momentum in 2025Stop Loss & Weekly Breakout Opportunity Watchlist - Улправда
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care - Ortho Spine News
Will Pacira BioSciences Inc. (82P) stock deliver stable dividendsJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
How geopolitical tensions affect Pacira BioSciences Inc. stockWeekly Profit Report & Safe Capital Preservation Plans - DonanımHaber
Why Pacira BioSciences Inc. stock remains a top recommendationJuly 2025 PreEarnings & Short-Term High Return Strategies - DonanımHaber
How rising interest rates impact Pacira BioSciences Inc. stockQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Pacira BioSciences (PCRX): Assessing Valuation After New PROBE Consortium Osteoarthritis AI Initiative - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock nowJuly 2025 Highlights & Free Reliable Trade Execution Plans - Улправда
Pacira (PCRX) Joins Global Effort to Enhance Osteoarthritis Rese - GuruFocus
Pacira BioSciences (PCRX): Reassessing Valuation After a 45% Year‑to‑Date Share Price Rally - Yahoo Finance
Pacira BioSciences stock earns technical rating upgrade - MSN
Pacira BioSciences (PCRX) Is Up 7.7% After Positive Spine Pain Pilot Data and New FDA ClearanceHas The Bull Case Changed? - Sahm
Pacira BioSciences Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares - MarketBeat
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock - MarketBeat
Pacira Biosciences CFO cross sells $626k in shares By Investing.com - Investing.com India
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Pacira BioSciences CFO Shawn Cross Sells 25,000 Shares - TradingView — Track All Markets
CFO Cross Sells 25,000 ($626.8K) Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
Natixis Buys 151,250 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
(PCRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
CFO Cross Files To Sell 9,104 Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Pacira BioSciences (NASDAQ:PCRX) Upgraded to Hold at Barclays - MarketBeat
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
8.30%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):